Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)

Detalles Bibliográficos
Autores principales: Takeda, Yasutaka, Sakuma, Ichiro, Hiramitsu, Shinya, Okada, Mizuho, Ueda, Shinichiro, Sakurai, Masaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061344/
https://www.ncbi.nlm.nih.gov/pubmed/37008309
http://dx.doi.org/10.3389/fcvm.2023.1172664
_version_ 1785017269366030336
author Takeda, Yasutaka
Sakuma, Ichiro
Hiramitsu, Shinya
Okada, Mizuho
Ueda, Shinichiro
Sakurai, Masaru
author_facet Takeda, Yasutaka
Sakuma, Ichiro
Hiramitsu, Shinya
Okada, Mizuho
Ueda, Shinichiro
Sakurai, Masaru
author_sort Takeda, Yasutaka
collection PubMed
description
format Online
Article
Text
id pubmed-10061344
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100613442023-03-31 Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study) Takeda, Yasutaka Sakuma, Ichiro Hiramitsu, Shinya Okada, Mizuho Ueda, Shinichiro Sakurai, Masaru Front Cardiovasc Med Cardiovascular Medicine Frontiers Media S.A. 2023-03-16 /pmc/articles/PMC10061344/ /pubmed/37008309 http://dx.doi.org/10.3389/fcvm.2023.1172664 Text en © 2023 Takeda, Sakuma, Hiramitsu, Okada, Ueda and Sakurai. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Takeda, Yasutaka
Sakuma, Ichiro
Hiramitsu, Shinya
Okada, Mizuho
Ueda, Shinichiro
Sakurai, Masaru
Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)
title Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)
title_full Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)
title_fullStr Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)
title_full_unstemmed Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)
title_short Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)
title_sort corrigendum: the effects of pemafibrate and omega-3 fatty acid ethyl on apob-48 in dyslipidemic patients treated with statin: a prospective, multicenter, open-label, randomized, parallel group trial in japan (proud48 study)
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061344/
https://www.ncbi.nlm.nih.gov/pubmed/37008309
http://dx.doi.org/10.3389/fcvm.2023.1172664
work_keys_str_mv AT takedayasutaka corrigendumtheeffectsofpemafibrateandomega3fattyacidethylonapob48indyslipidemicpatientstreatedwithstatinaprospectivemulticenteropenlabelrandomizedparallelgrouptrialinjapanproud48study
AT sakumaichiro corrigendumtheeffectsofpemafibrateandomega3fattyacidethylonapob48indyslipidemicpatientstreatedwithstatinaprospectivemulticenteropenlabelrandomizedparallelgrouptrialinjapanproud48study
AT hiramitsushinya corrigendumtheeffectsofpemafibrateandomega3fattyacidethylonapob48indyslipidemicpatientstreatedwithstatinaprospectivemulticenteropenlabelrandomizedparallelgrouptrialinjapanproud48study
AT okadamizuho corrigendumtheeffectsofpemafibrateandomega3fattyacidethylonapob48indyslipidemicpatientstreatedwithstatinaprospectivemulticenteropenlabelrandomizedparallelgrouptrialinjapanproud48study
AT uedashinichiro corrigendumtheeffectsofpemafibrateandomega3fattyacidethylonapob48indyslipidemicpatientstreatedwithstatinaprospectivemulticenteropenlabelrandomizedparallelgrouptrialinjapanproud48study
AT sakuraimasaru corrigendumtheeffectsofpemafibrateandomega3fattyacidethylonapob48indyslipidemicpatientstreatedwithstatinaprospectivemulticenteropenlabelrandomizedparallelgrouptrialinjapanproud48study

Ejemplares similares